Travere Therapeutics (TVTX) Shares Surge 44% After FDA Greenlights FILSPARI for Rare Kidney Disease

TLDR

• Travere Therapeutics (TVTX) shares soared 44% following FDA approval of FILSPARI for FSGS, a rare kidney condition
• FILSPARI has become the first and sole FDA-approved therapy for FSGS
• The approval is for adults and children 8 years of age and older who do not have nephrotic syndrome
• The potential U.S. patient population is estimated to exceed 30,000
• Guggenheim increased its price target for TVTX to $54 from $49, reiterating a Buy rating

---

(SeaPRwire) –   Travere Therapeutics (TVTX) shares surged 44% on Tuesday after the FDA cleared FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis — a rare kidney disease that previously lacked an approved therapy.

Travere Therapeutics, Inc., TVTX

The approval applies to adults and children aged 8 and above with FSGS who are not diagnosed with nephrotic syndrome. This establishes FILSPARI as the first and only drug approved by the FDA for FSGS.

This also represents the second rare kidney disease indication for FILSPARI, which is already approved for IgA nephropathy.

Travere projects the eligible U.S. patient population to be more than 30,000 individuals with FSGS who fit the criteria — specifically those lacking the three concurrent markers of nephrotic syndrome.

What the Trial Data Showed

The approval was supported by the Phase 3 DUPLEX Study, which is noted as the largest interventional trial ever conducted in FSGS.

Patients receiving FILSPARI experienced a 46% reduction in proteinuria from baseline to Week 108. Those on the comparator drug, a maximum dose of irbesartan, saw a 30% reduction.

In the specific sub-group without nephrotic syndrome, FILSPARI achieved a 48% reduction in proteinuria compared to 27% for irbesartan.

FILSPARI-treated patients in that group also demonstrated a benefit in eGFR, showing a treatment difference of 1.1 mL/min/1.73 m² at Week 108.

The drug exhibited a safety profile similar to irbesartan in both adult and pediatric patients — a favorable outcome that is significant for commercial adoption.

Analyst Reaction

Guggenheim analyst Vamil Divan lifted his price target on TVTX to $54 from $49 and maintained a Buy rating after the announcement.

Divan stated that the final label was more favorable than anticipated, observing that the approved patient group was wider than the market had expected.

In particular, the label includes both primary and secondary FSGS — rather than only the primary and genetic cases that analysts and management had considered the base scenario.

This broader scope creates a bigger commercial potential than was reflected in many valuations.

TipRanks notes another analyst Buy rating with a $47 price target for the stock and assesses the technical sentiment signal as a Buy.

TVTX’s market capitalization now stands at approximately $2.67 billion after Tuesday’s price movement.

The FDA approval was announced on April 13, 2026, with the stock’s reaction occurring during Tuesday’s trading session.